Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 208

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer

Open access
Panda, Anshuman, Mehnert, Janice M, Hirshfield, Kim M, Riedlinger, Greg, Damare, Sherri, Saunders, Tracie, Kane, Michael, Sokol, Levi, Stein, Mark N, Poplin, Elizabeth, Rodriguez-Rodriguez, Lorna, Silk, Ann W, Aisner, Joseph, Chan, Nancy, Malhotra, Jyoti, Frankel, Melissa, Kaufman, Howard L, Ali, Siraj, Ross, Jeffrey S, White, Eileen P, Bhanot, Gyan, Ganesan, Shridar · 2018 · JNCI: Journal of the National Cancer Institute

Abstract

Response to immune checkpoint therapy can be associated with a high mutation burden, but other mechanisms are also likely to be important. We identified a patient with metastatic gastric cancer with meaningful clinical benefit from treatment with the anti–programmed death–ligand 1 (PD-L1) antibody avelumab. This tumor showed no evidence of high mutation burden or mismatch repair defect but was strongly positive for presence of Epstein-Barr virus (EBV) encoded RNA. Analysis of The Cancer Genome Atlas gastric cancer data (25 EBV+, 80 microsatellite-instable [MSI], 310 microsatellite-stable [MSS]) showed that EBV-positive tumors were MSS. Two-sided Wilcoxon rank-sum tests showed that: 1) EBV-positive tumors had low mutation burden (median = 2.07 vs 3.13 in log10 scale, P < 10-12) but stronger evidence of immune infiltration (median ImmuneScore 2212 vs 1295, P < 10-4; log2 fold-change of CD8A = 1.85, P < 10-6) compared with MSI tumors, and 2) EBV-positive tumors had higher expression of immune checkpoint pathway (PD-1, CTLA-4 pathway) genes in RNA-seq data (log2 fold-changes: PD-1 = 1.85, PD-L1 = 1.93, PD-L2 = 1.50, CTLA-4 = 1.31, CD80 = 0.89, CD86 = 1.31, P < 10-4 each), and higher lymphocytic infiltration by histology (median tumor-infiltrating lymphocyte score = 3 vs 2, P < .001) compared with MSS tumors. These data suggest that EBV-positive low–mutation burden gastric cancers are a subset of MSS gastric cancers that may respond to immune checkpoint therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djx213

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 208

Metadata

Authors
Panda, A., Mehnert, J. M., Hirshfield, K. M., Riedlinger, G., Damare, S., Saunders, T., Kane, M., Sokol, L., Stein, M. N., Poplin, E., Rodriguez-Rodriguez, L., Silk, A. W., Aisner, J., Chan, N., Malhotra, J., Frankel, M., Kaufman, H. L., Ali, S., Ross, J. S., White, E. P., Bhanot, G., & Ganesan, S.
Venue
JNCI: Journal of the National Cancer Institute
Published
2017-11-15
Volume
110
Issue
3
Pages
316-320
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2769419513
Cited by
208
References
8
FWCI
7.76
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. https://app.cochat.ai/papers/10.1093/jnci/djx213
The paper
Panda, A., Mehnert, J. M., Hirshfield, K. M., Riedlinger, G., Damare, S., Saunders, T., Kane, M., Sokol, L., Stein, M. N., Poplin, E., Rodriguez-Rodriguez, L., Silk, A. W., Aisner, J., Chan, N., Malhotra, J., Frankel, M., Kaufman, H. L., Ali, S., Ross, J. S., . . . Ganesan, S. (2018). Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djx213

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.